Drug Development · global
Phase 3 Benefit-Risk Assessment Raises Concerns as Merck Ends All Nemtabrutinib Development
A data review from a Phase 3 trial has halted the entire development program for this blood cancer drug candidate. Specific risk and efficacy data have not been disclosed, and the clinical reasons behind the termination decision remain to be clarified.
For new blood cancer drugs, the ability to inhibit cancer cells must ultimately be weighed against the risks patients face. Merck, known as MSD outside the United States and Canada, announced on November 17 that it was terminating all clinical development of the oral drug candidate nemtabrutinib. The decision stemmed from a benefit-risk review of the Phase 3 BELLWAVE-011 trial and extends to the entire BELLWAVE program.
According to the company’s announcement, an external data monitoring committee reviewed the BELLWAVE-011 results and concluded that the treatment benefits in the trial might not outweigh the risks. Merck subsequently conducted a comprehensive review of the data and confirmed this assessment. In addition to stopping that trial, it decided to terminate the broader development effort, including two other Phase 3 studies, BELLWAVE-008 and BELLWAVE-010.
Nemtabrutinib, also known as MK-1026, is an investigational noncovalent Bruton’s tyrosine kinase (BTK) inhibitor designed to suppress B-cell receptor signaling associated with cancer cell growth. The BELLWAVE program was intended to evaluate its therapeutic potential in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other hematologic malignancies.
BELLWAVE-011 enrolled previously untreated patients with CLL or SLL and compared nemtabrutinib with the physician’s choice of ibrutinib or acalabrutinib. The study was designed to assess both efficacy measures, including tumor response and progression-free survival, and safety. This assessment therefore concerns whether the new drug could offer sufficient overall clinical value compared with existing treatment options.
However, the announcement has not specified the types or rates of adverse events or the efficacy data for each group that led to the termination decision. It is currently impossible to determine whether the issue primarily involved toxicity, insufficient efficacy, or a combination of both; nor can the same risks be extrapolated to all BTK inhibitors on this basis. The discontinuation of the other two Phase 3 trials as part of the overall program’s termination also does not mean that each had independently produced the same results.
Merck said it was notifying investigators participating in the trials, and that the study teams and physicians would discuss next steps and treatment options with patients. Data analyses for the trials are ongoing, and the company has committed to sharing the results with the scientific community. Whether the complete data can explain where this drug lost its balance between benefits and risks will be key to understanding the termination of its development.